MedWatch

Former CEO left Y-mabs with USD 10.7m in severance pay

Claus Møller was at the helm of the Danish-American biotech firm for six years until he quit at a moment’s notice – and apparently left with a sizable severance package.

Y-mabs is based in New York | Photo: Andrew Kelly/Reuters/Ritzau Scanpix

Y-mabs has been tight-lipped about why its former chief executive, Claus Møller, suddenly decided to step down in April from both the CEO role and his position at the company’s board of directors.

The Danish-American firm has not said anything about the terms of the the CEO’s departure – until now, as the company’s second quarter report for 2022 reveals an ostensibly lucrative severance package for Møller.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs